Regeneron (REGN) Receives a Hold from J.P. Morgan


In a report issued on September 28, Cory Kasimov from J.P. Morgan maintained a Hold rating on Regeneron (NASDAQ: REGN). The company’s shares closed yesterday at $394.23.

According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 3.0% and a 42.6% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Jounce Therapeutics Inc, and Acorda Therapeutics.

The word on The Street in general, suggests a Hold analyst consensus rating for Regeneron with a $399.73 average price target, which is a 1.4% upside from current levels. In a report issued on September 30, Cantor Fitzgerald also initiated coverage with a Hold rating on the stock with a $415 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $477 and a one-year low of $281.89. Currently, Regeneron has an average volume of 708.5K.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases. It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts